MicroRNAs (miRNAs) act as crucial post-transcriptional regulators of large gene networks, and their aberrant expression drives key oncogenic processes such as epithelial-mesenchymal transition (EMT), angiogenesis, immune evasion, and metastasis. Oncogenic miRNAs that lose tissue specificity during malignant transformation represent promising therapeutic targets, as their restricted expression in healthy organs could minimize off-target effects. To identify these candidates, this study performed a comprehensive pan-cancer analysis integrating tissue-specificity profiles of healthy tissues from the GTEx project with tumor data from the TCGA, TARGET, CGCI, and CPTAC cohorts. By combining profiling with differential expression analysis between tumor and matched normal samples, cross-cohort integration revealed that malignant transformation is characterized by a widespread loss of tissue-specific miRNA expression. Among these altered patterns, a cluster of nine oncomiRs was identified: miR-105-5p, miR-1269a, miR-196a-5p, miR-9-5p, miR-96-5p, miR-210-3p, miR-301b-3p, miR-592, and miR-135b-5p. These specific miRNAs were significantly and recurrently upregulated across various solid tumors. Functional enrichment analysis of their experimentally validated targets demonstrated a clear convergence on shared oncogenic pathways, particularly those governing hypoxia response, PI3K/AKT signaling, EMT, angiogenesis, and immune modulation.
Poptsova, M., Ismailov, A., Belogurov, A., Evpak, A.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0